Joseph Campain

Joseph Campain

Auto-generated profile, based on publicly available information

Joseph Campain

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA (J.C., C.G., C.N., S.M., I.G., F.M., A.M., C.P., L.R., I.L., N.I., R.M., G.D.L.).

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Journal of Cardiac Failure
Verified
Journal Article
Open access
JCJoseph Campain
Joseph Campain
IGIlya Giverts
Ilya Giverts
MSMark W. Schoenicke
Mark W. Schoenicke
JSJohn Sbarbaro
John Sbarbaro
CGCatharine Griskowitz
Catharine Griskowitz
GLGregory D. Lewis
Gregory D. Lewis

14 October 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
KLKenneth Lim
Kenneth Lim
MNMatthew Nayor
Matthew Nayor
EAEliott Arroyo
Eliott Arroyo
HBHeather N. Burney
Heather N. Burney
XLXiaochun Li
Xiaochun Li
GLGregory D. Lewis
Gregory D. Lewis
Key Points: Mild-to-moderate CKD is associated with impairment in cardiovascular functional capacity as assessed by oxygen uptake at peak exercise (VO 2 Peak). Cardiac output is significantly reduced in patients with mild-to-moderate CKD and is associated with impaired VO 2 Peak. Assessment of VO 2 Peak by cardiopulmonary exercise testing can detect decrements in cardiovascular function during early stages of kidney function decline that may not be captured using resting left ventricular geometric indices alone. Background: Traditional diagnostic tools that assess resting cardiac function and structure fail to accurately reflect cardiovascular alterations in patients with CKD. This study sought to determine whether multidimensional exercise response patterns related to cardiovascular functional capacity can detect abnormalities in mild-to-moderate CKD. Methods: In a cross-sectional study, we examined 3075 participants from the Framingham Heart Study (FHS) and 451 participants from the Massachusetts General Hospital Exercise Study (MGH-ExS) who underwent cardiopulmonary exercise testing. Participants were stratified by eGFR: eGFR ≥90, eGFR 60–89, and eGFR 30–59. Our primary outcomes of interest were peak oxygen uptake (VO 2 Peak), VO 2 at anaerobic threshold (VO 2 AT), and ratio of minute ventilation to carbon dioxide production (VE/VCO 2 ). Multiple linear regression models were fitted to evaluate the associations between eGFR group and each outcome variable adjusted for covariates. Results: In the FHS cohort, 1712 participants (56%) had an eGFR ≥90 ml/min per 1.73 m 2 , 1271 (41%) had an eGFR of 60–89 ml/min per 1.73 m 2 , and 92 (3%) had an eGFR of 30–59 ml/min per 1.73 m 2 . In the MGH-ExS cohort, 247 participants (55%) had an eGFR ≥90 ml/min per 1.73 m 2 , 154 (34%) had an eGFR of 60–89 ml/min per 1.73 m 2 , and 50 (11%) had an eGFR of 30–59 ml/min per 1.73 m 2 . In FHS, VO 2 Peak and VO 2 AT were incrementally impaired with declining kidney function ( P < 0.001); however, this pattern was attenuated after adjustment for age. Percent-predicted VO 2 Peak at AT was higher in the lower eGFR groups ( P < 0.001). In MGH-ExS, VO 2 Peak and VO 2 AT were incrementally impaired with declining kidney function in unadjusted and adjusted models ( P < 0.05). VO 2 Peak was associated with eGFR ( P < 0.05) in all models even after adjusting for age. On further mechanistic analysis, we directly measured cardiac output (CO) at peak exercise by right heart catheterization and found impaired CO in the lower eGFR groups ( P ≤ 0.007). Conclusions: Cardiopulmonary exercise testing–derived indices may detect impairment in cardiovascular functional capacity and track CO declines in mild-to-moderate CKD.

5 May 2026 in Circulation
Verified
Journal Article
Open access
ILIsabela Landsteiner
Isabela Landsteiner
LSLindsey K. Stolze
Lindsey K. Stolze
TPTess E. Peterson
Tess E. Peterson
APAndrew Perry
Andrew Perry
PLPhillip Lin
Phillip Lin
GLGregory D. Lewis
Gregory D. Lewis
BACKGROUND: Exercise unmasks limitations in multiorgan system reserve capacity characteristic of heart failure with preserved ejection fraction (HFpEF). However, the metabolic and genetic underpinnings of exercise deficits and their cumulative contribution to HFpEF severity and prognosis remain incompletely understood. METHODS: We used invasive cardiopulmonary exercise testing, metabolite profiling, and genomics to simultaneously characterize 7 exercise physiological deficits in patients with HFpEF: reduced exercise stroke volume and heart rate, steep pulmonary capillary wedge pressure/cardiac output slope, elevated pulmonary vascular resistance, pulmonary mechanical limitation to exercise, impaired peripheral oxygen extraction, and obesity-related exaggerated metabolic cost of initiating exercise. We first mapped the distribution, functional, and prognostic significance of these exercise deficits. We then applied least absolute shrinkage and selection operator regression to identify metabolite signatures of each exercise deficit and measured the relation of these signatures with clinical-demographic features, cardiac magnetic resonance imaging, and incident heart failure in 6345 individuals in the MESA study (Multi-Ethnic Study of Atherosclerosis) with ≈20 years of follow-up. Last, we mapped deficit-implicated metabolites to tissue-specific genetic variation in ≈2 million individuals, including ≈153 000 with heart failure, leveraging the largest genome-wide association studies of HFpEF comorbidities (obesity, renal disease, diabetes) to evaluate shared metabolic mechanisms of HFpEF pathophysiology. RESULTS: Our invasive cardiopulmonary exercise testing HFpEF cohort (age, 61.7±14.1 years; 54% female; body mass index, 30.6±6.7 kg/m 2 ) exhibited a broad range of compound cardiac and extracardiac exercise deficits. Individuals with ≥5 exercise deficits had a nearly 4-fold higher hazard of incident cardiovascular event or mortality (hazard ratio, 3.90 [95% CI, 1.74–8.75]; P <0.0001). The metabolite signature of exercise pulmonary capillary wedge pressure/cardiac output slope conferred a hazard ratio of 1.43 per 1-SD increment (95% CI, 1.20–1.71; P <0.001) for incident heart failure in MESA. Addition of all invasive cardiopulmonary exercise testing deficit metabolic signatures in a single model yielded ≈20% continuous net reclassification improvement over traditional HFpEF risk factors. Genes implicated by the exercise deficit metabolome were enriched in the heart failure genome-wide association study (≈2 million) and shared with obesity, renal dysfunction, and diabetes, highlighting a lifelong shared predisposition to heart failure (including HFpEF) and its comorbidities. CONCLUSIONS: Organ-specific responses to exercise and their circulating metabolite signatures are strongly linked to HFpEF development and prognosis. These results offer a paradigm for parsing HFpEF subphenotypes and prioritizing metabolic mechanisms of HFpEF.

7 July 2025 in Circulation Research
Verified
Journal Article
Open access
ILIsabela Landsteiner
Isabela Landsteiner
TITakenori Ikoma
Takenori Ikoma
ARAshvita Ramesh
Ashvita Ramesh
JCJoseph Campain
Joseph Campain
LCLaura P. Cohen
Laura P. Cohen
GLGregory D. Lewis
Gregory D. Lewis

5 September 2025 in Circulation
Verified
Journal Article
Open access
JCJoseph Campain
Joseph Campain
CGCatharine Griskowitz
Catharine Griskowitz
CNChloe Newlands
Chloe Newlands
BCBrian L. Claggett
Brian L. Claggett
IKIan J. Kulac
Ian J. Kulac
GLGregory D. Lewis
Gregory D. Lewis
BACKGROUND: Post-exercise oxygen uptake recovery (VO 2 Rec) is slow in advanced heart failure. We sought to establish easily derived VO 2 Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VO 2 Rec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy. METHODS: VO 2 Rec patterns were evaluated in relation to cardiac performance and the primary outcome of heart failure hospitalization death in a referral cohort with dyspnea on exertion undergoing cardiopulmonary exercise testing with hemodynamic monitoring (MGH-ExS [Massachusetts General Hospital Exercise Study]). We then investigated longitudinal measures of VO 2 Rec in the pivotal phase 3 randomized controlled trial SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in Hypertrophic Cardiomyopathy) of aficamten versus placebo for 24 weeks in participants with symptomatic obstructive hypertrophic cardiomyopathy. For both cohorts, VO 2 Rec was uniformly measured as time for VO 2 to decline by >0%, 12.5% (VO 2 T 12.5% ), 25%, and 50% of peak VO 2 . RESULTS: Among 814 MGH-ExS patients (58±16 years of age, 58% women), those with a longer VO 2 T 12.5% (≥35 versus <35 seconds) demonstrated elevated exercise pulmonary capillary wedge pressure to cardiac output slope ( P <0.0001) with no difference in peripheral oxygen extraction ( P =0.11). For each 15-second increase in VO 2 T 12.5% , the hazard ratio for heart failure hospitalization and all-cause death was 1.54 (95% CI, 1.35–1.76; P <0.001). In SEQUOIA-HCM participants with cardiopulmonary exercise testing at baseline and week 24 (n=263, 59.1±2.9 years of age, 41% women), baseline VO 2 T 12.5% was 45±20 seconds and improved 8 seconds (95% CI, −12 to −5 seconds; P <0.001) with aficamten treatment compared with placebo at 24 weeks. Participants treated with aficamten versus placebo were more likely to improve VO 2 T 12.5% by ≥15 seconds (odds ratio [OR], 3.7 [95% CI, 1.9–6.9]; number needed to treat=4.8). Shortening of VO 2 T 12.5% correlated with reduced NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin I, and left ventricular outflow tract gradient (all P <0.005). CONCLUSIONS: This study established VO 2 T 12.5% as a new measure that reflects cardiac performance during exercise and predicted heart failure event-free survival. Furthermore, VO 2 T 12.5% improved proportional to improvements in left ventricular outflow tract gradient and cardiac biomarkers in response to aficamten treatment, a cardiospecific therapy for obstructive hypertrophic cardiomyopathy. The simplicity and physiological relevance of VO 2 T 12.5% support its regular inclusion in cardiopulmonary exercise testing protocols evaluating cardiac function during exercise. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05186818.